AnHorn Medicines announced today that its lead neuroprotective candidate AH-008, under development to prevent chemotherapy-induced peripheral neuropathy, has reached two important regulatory achievements: Investigational New Drug clearance from the U.S. Food and Drug Administration and Index Case designation from the Taiwan Center for Drug Evaluation.

These accomplishments confirm the scientific approach supporting AH-008 and represent a major advance in bringing a novel preventive treatment for CIPN into clinical stages.

Addressing a Critical Unmet Need in Oncology

Chemotherapy-induced peripheral neuropathy ranks among the most frequent and treatment-limiting side effects linked to common cancer therapies such as taxanes, platinum compounds, vinca alkaloids, and antibody-drug conjugates. This condition can produce lasting nerve injury, resulting in pain, sensory loss, and prolonged disability that greatly reduces patient well-being.

In addition to patient impact, CIPN frequently leads to chemotherapy dose adjustments, postponements, or stops, which can weaken treatment success. Although widespread and burdensome, no approved options currently exist to prevent CIPN, underscoring a significant gap in oncology supportive care.

Regulatory Milestones: IND Clearance and Index Case Designation

The U.S. FDA IND clearance permits AH-008 to proceed into human clinical studies after thorough evaluation of its preclinical pharmacology, toxicology, and manufacturing information. This approval confirms the strength of the safety data and overall development plan.

The Taiwan CDE Index Case designation identifies AH-008 as a reference program for innovative drug development in its class. This status highlights the candidate's scientific novelty and capacity to meet an unmet clinical need while supporting smoother regulatory engagement.

Collectively, these steps show solid regulatory support across key agencies and highlight the translational quality of the AH-008 program.

Regulatory and Translational Validation

Preclinical work on AH-008 followed the U.S. FDA Draft Guidance from January 2025 on Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. This document details FDA standards for CIPN preventive agents, stressing clinically relevant neurotoxicity models and translational measures that link nerve protection to practical functional results.

AH-008 showed consistent neuroprotective activity across several chemotherapy-induced neuropathy models, maintaining peripheral nerve structure without reducing chemotherapy effectiveness. These prevention-focused experiments aimed to stop neuropathy development rather than manage existing symptoms, emphasizing AH-008's promise as an early intervention strategy.

Combined with U.S. FDA IND clearance, the findings position AH-008 as a first-in-class neuroprotective candidate prepared for clinical testing under current regulatory standards.

Rapid Translation from Preclinical to IND

AnHorn Medicines moved AH-008 from preclinical research to FDA IND clearance within 12 months, illustrating the firm's cohesive development strengths. This swift progress reflects AnHorn's skill in combining translational science, regulatory planning, and CMC efforts into an efficient process, showcasing its capacity to advance first-in-class programs addressing pressing medical needs.

About AH-008

AH-008 is a first-in-class neuroprotective candidate created to prevent chemotherapy-induced peripheral neuropathy through early targeting of chemotherapy-related nerve injury mechanisms. Rather than addressing symptoms after they appear, AH-008 acts at the start of the disease process to safeguard peripheral nerve function throughout cancer treatment.

About AnHorn Medicines

Established in 2020, AnHorn Medicines is an AI-focused biotech firm dedicated to novel small molecules and protein degraders for aesthetic medicine, oncology, and cancer supportive care. Its proprietary AIMCADD AI platform combines generative AI with molecular simulation to create potent, safe, and patentable drug candidates with high efficiency.

AnHorn is transforming AI application in drug discovery by speeding innovation, supporting precision medicine, and fostering a more sustainable therapeutic development environment.

Forward-Looking Statements

This press release includes forward-looking statements about the development, regulatory status, and possible clinical and commercial advantages of AH-008. Actual outcomes could vary substantially due to risks and uncertainties common in drug development, regulatory processes, and clinical results.

SOURCE AnHorn Medicines